<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>144498</routedMedId>
		<routedMedName>Aranesp (in polysorbate) inj</routedMedName>
		<routedGenericName>darbepoetin alfa in polysorbate injection</routedGenericName>
		<etcIds>
			<etc_id>788</etc_id>
		</etcIds>
		<medIds>
			<medId>546190 546192 546205 546186 546041 546187 546188 546054 546174 546047 546045 546043 546050 545587 546052 </medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Anemia Due to Renal Failure</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.808</icd9>
			<symbolic/>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
		  <concurrentTherapyExclusion>
		    <criteriaSet>  
		      <excludedTherapy>
		        <treatment>  
		          <treatmentLine> 
		            <option>WITH</option>
		            <interventionType>drug</interventionType>
		            <name/>
		            <codeValues/>
		            <selectedListName/>
		            <selectedListClassCode/>
		          </treatmentLine>
		        </treatment>
		      </excludedTherapy>
		    </criteriaSet>
		  </concurrentTherapyExclusion>
			<dosing>
				<text>0.45 mcg/kg intravenously or subcutaneously weekly, or 0.75 mcg/kg intravenously or subcutaneously every 2 weeks (on dialysis)</text>
				<text>0.45 mcg/kg intravenously or subcutaneously at 4 week intervals (not on dialysis)</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Aranesp (darbepoetin alfa). Physician Prescribing Information [Internet] Amgen Inc. 2012 Jul Accessed at: http://www.aranesp.com/. [created 2001; accessed 2013 Dec 3] </reference>
				<reference>Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease. American Journal of Geriatric Pharmacotherapy 2008;6(2):49-60. DOI: 10.1016/j.amjopharm.2008.05.002.</reference>
				<reference>Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opinion on Pharmacotherapy 2012;13(4):495-503. DOI: 10.1517/14656566.2012.658369.</reference>
				<reference>Amgen announces modifications to U.S. prescribing information for use of erythropoiesis-stimulating agents in chronic kidney disease. (press release detail) [Internet] Amgen Inc. 2011 Jun 24 Accessed at: http://wwwext.amgen.com/. [accessed 2013 Oct 10]</reference>
				<reference>Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney International 2012;82(2):235-41. DOI: 10.1038/ki.2012.76.</reference>
				<reference>Palmer SC, et al. Systematic review: erythropoiesis-stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine 2010;153(1):23-33. DOI: 10.1059/0003-4819-153-1-201007060-00252.</reference>
				<reference>Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009;361(21):2019-32. DOI: 10.1056/NEJMoa0907845.</reference>
				<reference>Solomon SD, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine 2010;363(12):1146-55. DOI: 10.1056/NEJMoa1005109.</reference>
				<reference>McMahon LP, MacGinley R, KHA-CARI. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology 2012;17(1):17-9. DOI: 10.1111/j.1440-1797.2011.01535.x.</reference>
				<reference>Johansen KL, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrology, Dialysis, Transplantation 2012;27(6):2418-25. DOI: 10.1093/ndt/gfr697.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Chemotherapy-Induced Anemia</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.809</icd9>
			<symbolic/>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>2.25 mcg/kg subcutaneously weekly, or 500 mcg subcutaneously every 3 weeks</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Aranesp (darbepoetin alfa). Physician Prescribing Information [Internet] Amgen Inc. 2012 Jul Accessed at: http://www.aranesp.com/. [created 2001; accessed 2013 Dec 3] </reference>
				<reference>Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology 2010;21 Suppl 5:v244-7. DOI: 10.1093/annonc/mdq202. (Reaffirmed 2013 Nov)</reference>
				<reference>Rizzo JD, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of Clinical Oncology 2010;28(33):4996-5010. DOI: 10.1200/JCO.2010.29.2201.</reference>
				<reference>Tonia T, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.pub5.</reference>
				<reference>Glaspy J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. British Journal of Cancer 2010;102(2):301-15. DOI: 10.1038/sj.bjc.6605498.</reference>
				<reference>Vansteenkiste J, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer 2012;76(3):478-85. DOI: 10.1016/j.lungcan.2011.12.015.<?oxy_comment_start author="desaipa01" timestamp="20150202T084733-0800" comment="only included those references for now from MCG that stated darbepoetin or ESA"?></reference>
				<?oxy_comment_end?>
				<reference>Untch M, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Annals of Oncology 2011;22(9):1999-2006. DOI: 10.1093/annonc/mdq713.</reference>
				<reference>Glaspy J. Update on safety of ESAs in cancer-induced anemia. Journal of the National Comprehensive Cancer Network 2012;10(5):659-66.</reference>
				<reference>Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Medicare Coverage Database [Internet] Centers for Medicare and Medicaid Services. 2007 Jul Accessed at: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203. [accessed 2013 Oct 7]</reference>
				<reference>Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews 2010, (verified by Cochrane 2010 Sep), Issue 7. Art. No.: CD006704. DOI: 10.1002/14651858.CD006704.pub3.</reference>
				<reference>Juneja V, et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clinical Cancer Research 2008;14(11):3242-7. DOI: 10.1158/1078-0432.CCR-07-1872.</reference>
				<reference>Cancer-and chemotherapy-induced anemia. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v 2.2014; 2013 Jul Accessed at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed 2013 Oct 8]</reference>
				<reference>Mitka M. New oversight put in place for physicians giving anemia drugs to patients with cancer. Journal of the American Medical Association 2010;303(14):1355-6. DOI: 10.1001/jama.2010.359.</reference>
				<reference>Myelodysplastic syndromes. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v. 2.2014; 2013 May Accessed at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed 2013 Oct 9]</reference>
				<reference>Santini V, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research 2010;34(12):1576-88. DOI: 10.1016/j.leukres.2010.01.018.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Anemia in Cancer Patients Not Directly Related to Current Myelosuppressive Chemotherapy of a Nonmyeloid Malignancy - Inconclusive or Non-Supportive Evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Journal of the American Medical Association 2008;299(8):914-24. DOI: 10.1001/jama.299.8.914.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			
		</diagnosis>
		<diagnosis>
			<fqn>Aplastic Anemia - Inconclusive or Non-Supportive Evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Gurion R, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009;94(5):712-9</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			
		</diagnosis>
		<diagnosis>
			<fqn>Heart Failure - Inconclusive or Non-Supportive Evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Swedberg K, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. New England Journal of Medicine 2013;368(13):1210-9. DOI: 10.1056/NEJMoa1214865.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	
</paload>
